Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nadofaragene Firadenovec→

Nadofaragene Firadenovec Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1823059-12-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Non-replicating adenoviral vector gene therapy delivering interferon alfa-2b
Mechanism of action
An adenoviral vector delivers the human IFNα2b gene to bladder urothelial cells. Transduced cells express interferon alfa-2b locally, promoting antitumour immune responses and growth-inhibitory effects within the bladder.
Indications / reported uses
  • Treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours; for intravesical use only

Sources: NLM DailyMed — ADSTILADRIN, updated 24 March 2026 · FDA — ADSTILADRIN product information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nadofaragene Firadenovec Environmental Risk Assessment (ERA) (the Nadofaragene Firadenovec ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.